


GLOBAL REPORT


	No of participants	No of responded participants	Response percentage
Measles virus, antibodies, January, 1-2025	46	43	93.5 %

Summary




Summary	AVR success rate
Sample S001	98.7 %
Sample S002	98.7 %
Sample S003	100 %
Average:	99.1 %

Sample S001




Sample S001 results	Responded	AVR success rate	Count
	Clinical interpretation	97.1 %	45
	Measles virus IgG	100 %	44
	Measles virus IgM	100 %	41
	Total:	98.7 %	130

Sample S001 Clinical interpretation




Clinical interpretation	Interpretation	Further action	Interpretation count	Further action count	AVR success rate	Interpretation Score	Further action Score
	Acute/recent infection		33		100 %	4	
		New sample requested and referred to confirmation		2	-		-
		Referred to confirmation		8	-		-
		New sample requested		5	-		-
	No detectable antibodies		1		0 %	0	
		New sample requested		1	-		-
	Laboratory does not give clinical interpretation		11		-	-	
		Referred to confirmation		1	-		-
	Total:		45		97.1 %		

Sample S001 Measles virus IgG



Positive

Sample S001 Measles virus IgM




Positive

Measles virus IgG	Interpretation	Method	Interpretation count	Method count	AVR success rate	Interpretation Score
	Positive		44		100 %	2
		bioMerieux VIDAS Measles IgG		3		
		DiaSorin LIAISON Measles IgG		24		
		Diesse Chorus Measles IgG ELISA		1		
		Euroimmun Measles IgG EIA		6		
		NovaTec NovaLisa Measles IgG		2		
		Orgentec Anti-Measles Virus IgG		2		
		TestLine Clinical Diagnostics EIA Measles IgG		1		
		Vircell VirClia Measles IgG		4		
		Virion/Serion ELISA classic Measles IgG		1		
	Total:		44		100 %	


Measles virus IgM	Interpretation	Method	Interpretation count	Method count	AVR success rate	Interpretation Score
	Positive		41		100 %	2
		DiaSorin LIAISON Measles IgM		23		
		Diesse Chorus Measles IgM ELISA		1		
		Euroimmun Measles IgM EIA		5		
		In-house EIA		1		
		Microimmune Measles IgM Capture EIA		1		
		NovaTec NovaLisa Measles IgM		2		
		Orgentec Anti-Measles Virus IgM		2		
		TestLine Clinical Diagnostics EIA Measles IgM		1		
		Vircell VirClia Measles IgM		4		
		Virion/Serion ELISA classic Measles IgM		1		
	Total:		41		100 %	

Sample S002




Sample S002 results	Responded	AVR success rate	Count
	Clinical interpretation	97.1 %	45
	Measles virus IgG	100 %	44
	Measles virus IgM	100 %	41
	Total:	98.7 %	130

Sample S002 Clinical interpretation




Clinical interpretation	Interpretation	Further action	Interpretation count	Further action count	AVR success rate	Interpretation Score	Further action Score
	Old immunity or vaccinated		32		100 %	4	
	Does not indicate acute infection		1		100 %	4	
	No detectable antibodies		1		0 %	0	
		New sample requested		1	-		-
	Laboratory does not give clinical interpretation		11		-	-	
	Total:		45		97.1 %		

Sample S002 Measles virus IgG



Positive

Sample S002 Measles virus IgM




Negative

Measles virus IgG	Interpretation	Method	Interpretation count	Method count	AVR success rate	Interpretation Score
	Positive		44		100 %	2
		bioMerieux VIDAS Measles IgG		3		
		DiaSorin LIAISON Measles IgG		24		
		Diesse Chorus Measles IgG ELISA		1		
		Euroimmun Measles IgG EIA		6		
		NovaTec NovaLisa Measles IgG		2		
		Orgentec Anti-Measles Virus IgG		2		
		TestLine Clinical Diagnostics EIA Measles IgG		1		
		Vircell VirClia Measles IgG		4		
		Virion/Serion ELISA classic Measles IgG		1		
	Total:		44		100 %	


Measles virus IgM	Interpretation	Method	Interpretation count	Method count	AVR success rate	Interpretation Score
	Negative		41		100 %	2
		DiaSorin LIAISON Measles IgM		23		
		Diesse Chorus Measles IgM ELISA		1		
		Euroimmun Measles IgM EIA		5		
		In-house EIA		1		
		Microimmune Measles IgM Capture EIA		1		
		NovaTec NovaLisa Measles IgM		2		
		Orgentec Anti-Measles Virus IgM		2		
		TestLine Clinical Diagnostics EIA Measles IgM		1		
		Vircell VirClia Measles IgM		4		
		Virion/Serion ELISA classic Measles IgM		1		
	Total:		41		100 %	

Sample S003




Sample S003 results	Responded	AVR success rate	Count
	Clinical interpretation	-	45
	Measles virus IgG	-	44
	Measles virus IgM	100 %	41
	Total:	100 %	130

Sample S003 Clinical interpretation




Clinical interpretation	Interpretation	Further action	Interpretation count	Further action count	AVR success rate	Interpretation Score	Further action Score
	No detectable antibodies		8		-	-	
		New sample requested		1	-		-
	Old immunity or vaccinated		25		-	-	
	Laboratory does not give clinical interpretation		12		-	-	
		Referred to confirmation		1	-		-
	Total:		45				

Sample S003 Measles virus IgG



Sample S003 Measles virus IgM



Measles virus IgG	Interpretation	Method	Interpretation count	Method count	AVR success rate	Interpretation Score
	Negative		9		-	-
		bioMerieux VIDAS Measles IgG		1		
		Euroimmun Measles IgG EIA		6		
		NovaTec NovaLisa Measles IgG		1		
		TestLine Clinical Diagnostics EIA Measles IgG		1		
	Borderline		3		-	-
		bioMerieux VIDAS Measles IgG		2		
		NovaTec NovaLisa Measles IgG		1		
	Positive		32		-	-
		DiaSorin LIAISON Measles IgG		24		
		Diesse Chorus Measles IgG ELISA		1		
		Orgentec Anti-Measles Virus IgG		2		
		Vircell VirClia Measles IgG		4		
		Virion/Serion ELISA classic Measles IgG		1		
	Total:		44			


Measles virus IgM	Interpretation	Method	Interpretation count	Method count	AVR success rate	Interpretation Score
	Negative		41		100 %	2
		DiaSorin LIAISON Measles IgM		23		
		Diesse Chorus Measles IgM ELISA		1		
		Euroimmun Measles IgM EIA		5		
		In-house EIA		1		
		Microimmune Measles IgM Capture EIA		1		
		NovaTec NovaLisa Measles IgM		2		
		Orgentec Anti-Measles Virus IgM		2		
		TestLine Clinical Diagnostics EIA Measles IgM		1		
		Vircell VirClia Measles IgM		4		
		Virion/Serion ELISA classic Measles IgM		1		
	Total:		41		100 %	

Report Info

PARTICIPANTS

Altogether 46 laboratories from 17 countries participated in this EQA round.

REPORT INFO

The results are divided into groups according to the method stated by the laboratory and presented in laboratory-specific tables. Accepted results are marked with green color and laboratory’s own result with a black radio button . In the scoring report you will find summaries of overall success rate and sample specific success rates (%). Sample specific interpretations are shown in pie diagrams as percentages and the total interpretation and methodic counts in the tables. If you have not reported any results you will get a note: “You have not responded in time, only global report is available.”  
For information on report interpretation and performance evaluation, please see the "EQAS Interpretation guidelines" in LabScala User instructions. In case you have any questions regarding the reports, please contact the EQA Coordinator.

SCORING

The round is scored based on test results and clinical interpretations when 60% or more of the participants report the expected result and when at least three results are reported. The following general rules are applied:

- Correct/expected test result 2/2 points
- False/deviating test result 0/2 points
- Correct/expected clinical interpretation 4/4 points
- False/deviating clinical interpretation 0/4 points

The performance of the laboratory is assessed by the Own success rate (%). The target is 100%. The examination-specific scores obtained by the laboratory in the round are converted to Own success rate per sample (scores/maximum scores\*100). The Laboratory’s Own success rate is the average of the sample success rates. The success rate for the entire round (AVR success rate) is calculated from the total number of scores given to the results per sample (all scores/maximum scores\*100). The AVG success rate of the entire round is the average of the sample success rates. The difference in the Laboratory’s Own success rate (%) to the corresponding numbers for the entire round is shown in the table.